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The fornix is an integral white matter bundle located in the medial diencephalon and is part
of the limbic structures. It serves a vital role in memory functions and as such has become
the subject of recent research emphasis in Alzheimer’s disease (AD) and mild cognitive
impairment (MCI). As the characteristic pathological processes of AD progress, structural
and functional changes to the medial temporal lobes and other regions become evident
years before clinical symptoms are present.Though gray matter atrophy has been the most
studied, degradation of white matter structures especially the fornix may precede these
and has become detectable with use of diffusion tensor imaging (DTI) and other compli-
mentary imaging techniques. Recent research utilizing DTI measurement of the fornix has
shown good discriminability of diagnostic groups, particularly early and preclinical, as well
as predictive power for incident MCI and AD. Stimulating and modulating fornix function by
the way of DBS has been an exciting new area as pharmacological therapeutics has been
slow to develop.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common neurodegenerative
condition in aging. AD is a growing public health problem that
is projected to reach epidemic proportions if disease-modifying
therapies are not found. The latest figures from the Alzheimer’s
Association indicate that there are an estimated 5.3 million Amer-
icans living with AD. By 2050, an estimated 11–16 million people
are expected to be diagnosed in the United States alone (Thies et al.,
2013). Establishing the diagnosis of Mild Cognitive Impairment
(MCI) and AD has evolved over the last 25 years with the most
recent iteration of the National Institute on Aging and Alzheimer’s
Association criteria (Mckhann et al., 1984, 2011). These criteria
place a new emphasis on the use of biomarkers of AD pathophysi-
ology whereas the original criteria were based solely on the clinical
evaluation. Although the use of biomarkers to establish diagno-
sis or track progression is considered a step forward in the field,
there is a need for continued development of complementary tech-
nologies utilizing biological, physical, cognitive, and behavioral
substrates.
Broadly, the initial pathologic changes in AD have been shown
to involve the medial temporal lobes with the accumulation of
neurofibrillary tangles and senile beta amyloid plaques (Bancher
et al., 1993; Braak and Braak, 1995; Xu et al., 2000; Braak et al.,
2006). This region is thought to mediate the retrieval and learning
of semantic and episodic memory – the most common early cog-
nitive deficits in AD (Aggleton and Brown, 1999; Behl et al., 2005;
Levy and Chelune, 2007; Baldwin and Farias, 2009). The accumu-
lation of tangles and plaques is associated with progressive atrophy
of the cortical gray matter as loss of large pyramidal neurons
(layers III and IV) advances, particularly in cortical association
regions (Braak and Braak, 1995). In addition to this, several white
matter (WM) abnormalities have been described and are thought
to reflect axonal disintegration, rarefaction, oligodendrocytosis,
and astrocytosis (Xu et al., 2001; Roher et al., 2002; Shahani et al.,
2002). Neuroimaging techniques, particularly magnetic resonance
imaging (MRI), is a robust method used to visualize and detect
subtle changes in structure and function of the substructures
within the medial temporal lobe and related regions as important
and perhaps early markers of disease and progression.
Though most volumetric imaging studies focused on atrophy
of the entorhinal cortex and hippocampus, close inspection of the
limbic structures has revealed significant volume reductions in
patients with sporadic and familial AD (Decarli, 2001; Cash et al.,
2013). The fornix is one structure within the limbic system that is
receiving increasing attention recently in part because of its ease of
detectability using MRI scanning as well as robust associations to
cognitive changes, diagnostic group discrimination, and suscep-
tibility to therapeutic intervention (Aggleton and Brown, 1999;
Thomas et al., 2011). Because of the increasing interest in this
structure, this brief review will serve as an updated survey of the
key research over the last 10 years involving the fornix with hopes
for continued and increasing efforts to better understand the use of
this structure in the diagnosis, progression, and treatment of AD.
FORNIX – STRUCTURE AND FUNCTION
The fornix is a WM bundle belonging to the medial diencephalon,
which also includes the hippocampus, mammillary bodies, and
anterior and medial thalamus. Grossly, the fornix is found on the
medial aspects of the cerebral hemispheres connecting the medial
temporal lobes to the hypothalamus. It is formed at first from the
output fibers of the hippocampus in the mesial temporal lobe,
beneath the floor of the lateral ventricle. It courses along the curve
of the corpus callosum forming its body. At the level of the foramen
of Monro, the fornix divides and travels inferiorly and posteriorly
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in the lateral wall of the third ventricle to end in the hypothala-
mus and basal forebrain. Though the left and right fornices travel
separately along their course from the hippocampus to the hypo-
thalamus, they merge at the level of the forniceal body to form an
important commissural tract (Nolte, 1993; Aggleton and Brown,
1999; Brewer, 2003; Patestas Ma, 2006). See Figures 1A,B.
The fornix is but one structure within the“temporal lobe mem-
ory system” also termed the Papez circuit described by James
Papez in 1937 (Papez, 1995). The fornix has been demonstrated
as the link between the hippocampus, mammillary bodies of the
hypothalamus, and the anterior thalamic nuclei (via the mam-
milothalamic tract) (Nolte, 1993; Yamada et al., 1998; Aggleton
and Brown, 1999; Patestas Ma, 2006). Efferent projections from the
hippocampus to the medial diencephalon, particularly the anterior
thalamic nuclei, are thought to be essential for normal hippocam-
pal activity and are directed by the fornix, which then forms the
major cholinergic output tract for the hippocampus (Cassel et al.,
1997; Aggleton and Brown, 1999). Some of the earliest research
involving lesion studies of this system asserted that damage to this
axis resulted in anterograde amnesia, which occurs as a result of
faulty encoding of episodic information (Aggleton and Brown,
1999). Specifically, damage to the hippocampus, fornix, and other
diencephalic structures result in the inability to form declarative
(semantic and episodic) memories. Although selective damage of
the fornices has been shown to result in anterograde amnesia,
the damage to other structures within the Papez circuit result in
similar deficits emphasizes that the integrity of the circuit rather
than individual substructure is important.
FORNIX AS AN IMAGING BIOMARKER IN MCI AND AD
There has been increasing research in recent years on imaging
the fornix as a biomarker for diagnosis, progression (or con-
version), and cognition in MCI and AD. Some of the earliest
research focused on fornix ultrastructure as a sign of MCI and
AD. Much of this research employed MRI volumetric methods
and showed atrophy (volume reduction) in many of the limbic
lobe structures including the fornix. Early volumetric studies by
Callen et al. (2001) showed that a number of structures within the
Papez circuit (hippocampus, amygdala, anterior thalamus, hypo-
thalamus, mammillary bodies, basal forebrain, septal area, fornix,
orbitofrontal, and parahippocampal cortices) suffered significant
atrophy with hippocampal and posterior cingulate regions being
particularly affected. These early studies largely established com-
plimentary findings to neuropathological observations of limbic
atrophy in AD (Hopper and Vogel, 1976). The interest in estab-
lishing morphological changes in preclinical AD (MCI) as an
early marker of disease was first undertaken by Copenhaver et al.
(2006) who did not show significant atrophy of fornix or mam-
millary bodies in MCI as was initially hypothesized. The inability
to show this difference was likely due to the relative insensitiv-
ity of volumetric methods used at the time even though imaging
processes and analyses were improved upon compared to similar
FIGURE 1 |The fornix anatomy and DTI fornix sign. (A) Normal
neuroanatomy highlighting limbic structures. (B) 1. Fornix; 2. mammilary
body; 3. anterior thalamic nucleus; 4. hippocampus; 5. mammillothalamic
tract; and 6. entorhinal cortex. Adapted from Nieuwenhuys (2008). (C) FA map
of cognitively normal 80-year-old woman without fornix sign. (D) FA map of
80-year-old woman with Alzheimer’s disease with fornix sign. (C,D) FA maps
shown with magnified view of the fornix (fuchsia rectangle), adapted from
Oishi et al. (2011).
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previous studies (Gale et al., 1993; Bilir et al., 1998; Kuzniecky et al.,
1999; Callen et al., 2001). As a result, most recent research in the
area has focused on fornix microstructure as the measurement of
WM integrity. This renewed direction in imaging research of the
fornix was based on the hypothesis that the earliest morphological
changes occurred within medial temporal lobe gray matter, specif-
ically the hippocampus and entorhinal structures with secondary
effect to the efferent outflow tract through the fornix and mammil-
lary bodies (Braak and Braak, 1995; Cassel et al., 1997; Aggleton
and Brown, 1999). Needless to say, the underlying pathological
processes affect an interconnected network of regions rather than
single regions.
Diffusion tensor imaging has been the most commonly used
in vivo MRI technique in studying the WM architecture of the
fornix. Diffusion tensor imaging (DTI) is an indirect method of
measuring WM integrity when conventional MRI lacks the con-
trast to delineate WM fiber tract organization (Beaulieu et al.,1996;
Mori et al., 1999; Basser and Jones, 2002). Fractional anisotropy
(FA) and mean diffusivity (MD) are two DTI measures used to
quantify the integrity of WM microstructure by measuring the
relative random motion of water in cerebral tissue. These mea-
sures are scalar values where higher values of FA and lower values
of MD are thought to represent normal tissue cytoarchitecture
where the random motion of water along a healthy axon, for exam-
ple, is tightly constrained and restricted to movement along one
direction (anisotropic). Two additional measures, axial diffusivity
(DA) and radial diffusivity (DR) are associated with secondary
degeneration of axons and breakdown of myelin and may provide
additional detail into WM fiber integrity (Pierpaoli et al., 1996;
Song et al., 2003, 2004).
Relating DTI measurement with other biomarkers that are con-
sidered more direct ways of detecting AD pathology has shown
good correlation and has been a means of test validation. PET
amyloid imaging is a well-established method of directly mea-
suring AD pathology, β-amyloid (Aβ) deposition in vivo, but
clinical application has been limited by convenience of use, inva-
siveness, and the half-life of radiotracers. When compared with
DTI, several studies have shown positive correlation. A study
by Chao et al. (2013) showed Aβ deposition as measured by
Pittsburgh compound B (PiB) PET imaging was associated with
reduced WM integrity (lower FA) in the fornix and splenium
of the corpus callosum in subjects who ranged from normal to
MCI. Similarly, Racine et al. (2014) showed a positive correla-
tion between Aβ+ subjects and those with lower FA in the corpus
callosum, hippocampal cingulum, and lateral fornix. Compari-
son with CSF markers of AD pathology Aβ42 and p-Tau181 has
also been an important area of research. A study by Gold et al.
(2014) showed a positive correlation between these CSF markers
and WM integrity (FA) in the fornix, a relationship that per-
sisted after controlling for hippocampal and fornix volume in a
cohort of 20 cognitively normal older adults. Lower FA in the
fornix was also associated with reduced performance on several
cognitive tests including a Digit Symbol Test. This study is par-
ticularly important because CSF changes are thought to precede
neuroimaging alterations by several years (Jack et al., 2010). These
studies strongly suggest that microstructural measurements are
related to AD pathology.
As the interest in the field of identifying early markers of
AD continued to grow, several studies aimed to identify WM
changes in preclinical AD. One of the earlier studies by Ring-
man et al. (2007) found decreased FA in the columns of the
fornix were associated (linear regression) with hippocampal atro-
phy (p= 0.023), WM volume (p= 0.002), and mutation status
(p= 0.032) in asymptomatic familial AD. They concluded that
decreased FA in the forniceal columns is a robust finding in early
familial AD and may be a biomarker of early disease in sporadic
AD. Since this important study, there have been a number of more
recent DTI studies showing similar associations between the WM
tracts of the fornix and earlier preclinical stage. Cross-sectional
DTI analysis by Mielke et al. (2009) and longitudinal analysis of
the same cohort by Nowrangi et al. (2013) showed significant dif-
ferences between normal participants and those with MCI and AD
in the fornix, anterior cingulum, and splenium cross-sectionally
and longitudinally (p< 0.01). Decreases in FA cross-sectionally
and increases in MD longitudinally were observed in the fornix
and were thought to indicate early markers of disease and longi-
tudinal disease progression. Studies by Huang et al. (2012) and
Boespflug et al. (2013) offered full DTI characterization (FA, MD,
DA, and DR) of region of interest and atlas-based approaches
to WM analysis respectively in MCI and AD. Both studies showed
selective disruption of WM integrity in limbic structures including
the fornix with DR being most sensitive to changes in the fornix.
These studies further highlight a robust association between loss
of integrity within the limbic structures and decrease in cognitive
performance as illustrated by neuropsychological tests of episodic
memory. Taken together, these studies suggest that the limbic WM
tracts are preferentially affected in the early stages of cognitive dys-
function and that microstructural degradation of the fornix may
precede atrophy of the hippocampus as detected by MRI.
Identifying preclinical signs of AD have been complemented by
other research identifying individuals who would go on to progress
to AD or convert from MCI to AD. One of the first studies observ-
ing this was by Oishi et al. (2011) who identified the fornix on an
FA-scaled DTI map. FA reductions in this region predicted con-
version form normal to amnestic MCI (aMCI) with a specificity of
1.0 and sensitivity of 0.67 and conversion from aMCI to AD with a
specificity of 0.94 and sensitivity of 0.83. This finding was termed
“the fornix sign” and has shown promise as an early predictive
imaging sign of AD (See Figures 1C,D). Two other studies simi-
larly emphasized the use of fornix microstructure as a predictor of
conversion. One study by Van Bruggen et al. (2012) retrospectively
used DTI analysis to differentiate between a subgroup of aMCI
who converted to AD and a subgroup that did not. They found
that FA, DR, and DA changes within the fornix, cingulum, and the
corpus callosum were able to significantly discriminate between
the two diagnostic groups and therefore could be thought of as a
predictor for conversion between MCI and AD. Another study by
Douaud et al. (2013) compared two groups of MCI patients; one
that converted to AD no earlier than from baseline scanning and
another that remained stable without progression of symptoms for
at least 3 years. Comparing both volumetric and microstructural
variables including DTI anisotropy and diffusivity, they found sig-
nificant group differences in the body of the fornix, left fimbria,
and the superior longitudinal fasciculus. These studies emphasize
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the importance of microstructural integrity of the limbic lobe and
specifically the fornix in predicting the progression/conversion
from preclinical to clinical AD.
Recently, the field has been quite interested in identifying cog-
nitively normal individuals who might be at increased risk for
developing AD. The well-known and well-regarded hypothesis by
Jack et al. and others that imaging changes are evident before clin-
ical symptoms arise and that the pathological changes in the brain
begin even decades before those has prompted increased inter-
est in identifying these individuals (Morris et al., 1996; Bennett
et al., 2006; Jack et al., 2010, 2013). In line with previous hypothe-
ses that microstructural change precedes gross atrophic changes,
there has been increasing work in using DTI and complimentary
imaging methods to examine this. One study by Fletcher et al.
(2013) identified the fornix as a region of microstructural change
in cognitively normal elders. They found that the fornix body
volume and DA were highly significant predictors of cognitive
decline from normal cognition [r==0.47 (0.24–0.89), p= 0.02,
and r==1.25 (1.02–1.46), p= 0.005, respectively]. This is one of
the first studies establishing fornix degeneration as a predictor of
incipient cognitive decline among healthy elderly individuals. Two
studies conducted by Zhuang et al. (2012, 2013) demonstrated
that WM changes in the fornix were evident in preclinical AD.
One study (Zhuang et al., 2013) showed that when compared to
Table 1 | Summary of key biomarker research of the fornix in cognitively normal (NC), MCI, and AD.
Study Cohort Regions of interest and imaging findings Conclusion
Ringman
et al. (2007)
2 AD FA for mean whole brain WM, forniceal columns,
bilateral perforant pathways, left orbitofrontal lobe were
decreased relative to non-carriers
FA is reduced in the fornix in persons carrying
mutations for AD prior to symptoms of dementia and is
a better predictor of mutation status than other regions
21 at-risk AD
Mielke et al.
(2009)
25 NC Lower FA in fornix, anterior cingulum bundle, splenium
of the corpus collosum in AD vs. NC and AD vs. MCI
FA is decreased in specific fiber tracts including the
fornix in NC, MCI, and AD and may be an indicator of
progression over 3 months
25 MCI
25 AD
Nowrangi
et al. (2013)
25 NC Higher MD and lower FA in the fornix and splenium in
AD vs. MCI or NC of 12 months
Higher MD in the fornix longitudinally was a better
indicator of change than FA and may be an early
indicator of progression
25 MCI
25 AD
Huang et al.
(2012)
24 NC FA, MD, DR, DA of limbic, commissural, and association
tracts are differentially associated with diagnostic
group. Comparison between aMCI and NC show
differences only in limbic structures
WM disruption of limbic tract structures is caused by
neuronal damage in aMCI and indicates a progression
pattern between WM tracts
11 aMCI
26 AD
Boespflug
et al. (2013)
18 MCI Lower DR, higher FA, and lower MD in the fornix
associated with better paired associate learning
Disparate pathology of temporal stems and fornix WM
is associated with early memory impairment in MCI
Oishi et al.
(2011)
25 NC Fornix sign differentiated AD vs. NC and predicted
conversion from NC to aMCI and from aMCI to AD
The fornix sign may be a predictive biomarker sign of AD
24 aMCI
23 AD
Van Bruggen
et al. (2012)
15 NC Significant differences in FA and DR in the fornix,
corpus callosum, and cingulum in MCI who remained
stable vs. converters
DTI changes in MCI converters vs. those who remained
stable may be an early indicator of progression to AD17 MCI (8 stable,
9 converters)
15 AD
Douaud et al.
(2013)
13 aMCI
(converters)
Significant group differences in volume and
microstructure of left hippocampus, body of the fornix,
left fibria, and superior longitudinal fasciculus
Microstructural changes in left hippocampus using DTI
showed most substantial differences between two
diagnostic groups and was best predictor of future
progression to AD
22 aMCI (stable)
Fletcher et al.
(2013)
102 NC Fornix body volume and DA were highly significant
predictors of cognitive decline from normal cognition
Fornix degeneration in NC may be a predictor of
incipient cognitive decline among healthy elderly
individuals
Zhuang et al.
(2012)
173 NC (stable) aMCI converters had substantial reduction in FA in
precuneus, parahippocampal cingulum and gyrus, and
fornix while gray matter structures intact
Microstructural WM changes are present in NC in the
pre-aMCI stage and may be an imaging marker of early
AD-related brain changes
20 aMCI
(converted)
Zhuang et al.
(2013)
155 NC Late aMCI had lower WM integrity in the fornix,
parahippocampal cingulum, and uncinate fasciculus,
early aMCI showed white matter damage in fornix
Limbic WM tracts preferentially affected in early stages
of cognitive dysfunction particularly in the fornix, which
may precede hippocampal atrophy
27 “late” aMCI
39 “early” aMCI
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cognitively normal subjects and those with late MCI, early aMCI
subjects had lower WM integrity in the fornix. In a second study
(Zhuang et al., 2012), the same group showed that when compared
to normal subjects who remained stable over 2 years, those who
converted to aMCI had substantial reductions in WM integrity in
the fornix, parahippocampal gyrus WM, and cingulum while gray
matter structures remained relatively intact. FA was found to be a
predictor of conversion from cognitively normal to aMCI. Taken
together, these studies emphasize the continued importance of
detecting earlier preclinical forms of AD even in normal subjects
in order to identify patients who might benefit from interventional
approaches. Table 1 summarizes the key studies described above.
FORNIX AND CLINICAL TREATMENT IN AD
One of the most recent and exciting avenues of research has
been directed at enhancing cognition by stimulating or modu-
lating fornix function. Deep Brain Stimulation (DBS) has been
thought of for some time now as having significant effect on
mood and anxiety disorders such as major depression, obsessive
compulsive disorder as well as Gilles de Tourette’s syndrome, and
other conditions. Similarly, it has been hypothesized that DBS
may also play a role in enhancing memory functions. One of
the first studies in this area by Hamani et al. (2008) used DBS
to stimulate the fornix/hypothalamus area in a man with mor-
bid obesity. In a case observation report, they also described that
the procedure generated detailed autobiographical memory. In
AD, this same concept has been hypothesized as being a poten-
tial therapeutic intervention for the treatment of amnesia and has
just started being seriously studied. The first study of its kind,
by Laxton et al. (2010), performed DBS stimulation of the fornix
and hypothalamus in six AD patients. Though this was largely a
safety study, the authors found that DBS triggered neural activ-
ity (increased metabolism) in some patients as seen through PET
imaging (Laxton et al., 2010).
Later in vivo studies of DBS in patients with AD have been few
and largely with relatively low N. Since 1985, there have been just
two DBS studies targeting the stimulation of the fornix in patients
with AD (Laxton et al., 2010; Fontaine et al., 2013). Found to
over-all be safe, the clinical response has been rather modest with
MMSE scores stabilizing rather than improving. However, reversal
of AD-related hypometabolism has been observed in temporo-
parietal-occipital regions as well as increased connectivity between
similar regions representing distributed cognitive networks (Smith
et al., 2012). Given the lack of success thus far in developing
pharmacological therapies for AD and the slow pace of further
developments, such novel treatments as DBS is a promising avenue
for therapy in AD. Currently, the Advance DBS clinical trial has
recently completed recruitment of 42 participants with mild AD.
Half of the study participants will have the stimulators turned on
at the start of the study and the other half 12 months later. All
participants will be followed for 18 months to track progression
of their cognitive impairment. More information of this study can
be found at www.clinicaltrials.gov.
CONCLUSION
There is a small but growing body of research directed toward
the structure and function of the fornix in MCI and AD. Because
of its important role within the “temporal lobe memory system,”
understanding the microstructural integrity of the fornix in MCI
and AD has become an important area of focus in the field as
there is a growing priority for identifying individuals early in the
disease process and those who are at increased risk for progression
or conversion. Recent studies have shown DTI is able to indirectly
measure microstructural changes of the fornix that may precede
gross atrophic changes of gray matter structures such as the hip-
pocampus and entorhinal cortex. These studies demonstrate that
DTI measurements of the fornix can significantly discriminate
between cognitively normal, MCI, and AD groups thereby serving
as a robust biomarker of disease. Moreover, fornix measurements
have been shown to be a reliable measure of conversion from
preclinical disease to AD. As pharmacological interventions con-
tinue to develop, studies of stimulating the fornix through DBS
to alleviate or even reverse cognitive impairment has shown some
early promise in stabilizing cognitive decline and increasing neural
network activity.
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